Publication
CD200 is a potent new growth factor in Multiple Myeloma dependent on IGF1 receptor signaling.
Angélique Bruyer, Nicolas Robert, Jules Varbedian, Elvira Garcia De Paco, Lauryn Jaffory, Stéphanie Boireau, Christophe Hirtz, Jérôme Vialaret, Pierre Martineau, Bruno Robert, Guilhem Requirand, Guillaume Cartron, Laure Vincent, Charles Herbaux, Jérôme Moreaux, Caroline Bret
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
CD200 is an immune checkpoint aberrantly expressed in 70% of newly diagnosed patients with multiple myeloma (MM) and associated with a poor outcome. CD200 expression by tumor cells inhibits immune response through interaction with CD200R and participates in resistance to immune based therapies.…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available